UBS Group
ICCM icon

UBS Group’s IceCure Medical ICCM Stock Holding History

UBS Group’s Portfolio ICCM Stock Details ICCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.1K Buy
17,093
+11,953
+233% +$86.4K ﹤0.01% 7287
2026
Q1 		$46.4K Buy
5,140
+2,068
+67% +$37.8K ﹤0.01% 7413
2025
Q4 		$56.2K Buy
3,072
+2,351
+326% +$52.8K ﹤0.01% 7165
2025
Q3 		$22K Buy
721
+225
+45% +$6.72K ﹤0.01% 8089
2025
Q2 		$14.8K Buy
496
+424
+589% +$13.6K ﹤0.01% 8637
2025
Q1 		$2.54K Buy
+72
New +$2.82K ﹤0.01% 9312
2024
Q4 		– Sell
-1,996
Closed -$36.5K – 10141
2024
Q3 		$36.5K Buy
+1,996
New +$40.5K ﹤0.01% 7025
2024
Q1 		– Sell
-694
Closed -$22.3K – 9641
2023
Q4 		$22.3K Buy
694
+201
+41% +$5.32K ﹤0.01% 7042
2023
Q3 		$7.99K Buy
+493
New +$15.5K ﹤0.01% 7199
2023
Q2 		– Sell
-58
Closed -$1.99K – 9219
2023
Q1 		$1.99K Sell
58
-908
-94% -$33.8K ﹤0.01% 8612
2022
Q4 		$44.9K Buy
966
+897
+1,300% +$32.1K ﹤0.01% 6869
2022
Q3 		$3K Sell
69
-58
-46% -$2.86K ﹤0.01% 9542
2022
Q2 		$7K Sell
127
-9
-7% -$542 ﹤0.01% 8492
2022
Q1 		$10K Buy
136
+38
+39% +$2.95K ﹤0.01% 8416
2021
Q4 		$9K Buy
98
+7
+8% +$1.17K ﹤0.01% 8907
2021
Q3 		$24K Buy
+91
New +$27K ﹤0.01% 6966

Other funds holding ICCM

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $123M AUM 198.31% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GCM
Gunderson Capital Management Mt. Pleasant, South Carolina $370M AUM 211.56% 1-Year Est. Return
KFG
Kingdom Financial Group Peoria, Arizona $391M AUM 21.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
BCWM
Bartlett & Co Wealth Management Cincinnati, Ohio $7.99B AUM 20.76% 1-Year Est. Return

UBS Group's ICCM Position: Q2 2026 in Review

UBS Group increased its IceCure Medical (ICCM) stake by 233% in Q2 2026, buying an estimated $86.4K and bringing the position to 17,093 shares worth $83.1K. The position accounts for ﹤0.01% of the portfolio, ranked #7287.

UBS Group first reported a position in ICCM in Q3 2021 and has held it in 16 quarters since. 11 funds tracked by Wall St. Rank hold ICCM as of Q2 2026.

  • UBS Group held 17,093 shares of IceCure Medical worth $83.1K as of Q2 2026.
  • UBS Group bought 11,953 IceCure Medical shares in Q2 2026, an estimated $86.4K.
  • IceCure Medical made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7287 holding.
  • UBS Group first reported a position in IceCure Medical in Q3 2021 and has held it in 16 quarters since.
  • 11 funds tracked by Wall St. Rank held IceCure Medical as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.